MỐI LIÊN QUAN GIỮA NỒNG ĐỘ 25-HYDROXYVITAMIN D MÁU VÀ ALBUMIN NIỆU VI LƯỢNG Ở NGƯỜI BỆNH ĐÁI THÁO ĐƯỜNG TÍP 2
Nội dung chính của bài viết
Tóm tắt
Mục tiêu: Xác định tỷ lệ thiếu 25-Hydroxyvitamin D máu và phân tích mối liên quan giữa
25-Hydroxyvitamin D với albumin niệu vi lượng ở người bệnh đái tháo đường típ 2.
Đối tượng và phương pháp: Nghiên cứu mô tả cắt ngang trên 90 bệnh nhân đái tháo đường típ 2
điều trị nội trú tại Khoa Nội tiết – Nội thận Bệnh viện Đà Nẵng.
Kết quả: Tỷ lệ thiếu 25-Hydroxyvitamin D máu ở người bệnh đái tháo đường típ 2 là 20%. Nồng độ
25-Hydroxyvitamin D máu có mối tương quan nghịch với mức độ bài xuất albumin niệu (r = -0,216;
p < 0,05).
Chi tiết bài viết
Từ khóa
25-Hydroxyvitamin D, đái tháo đường, albumin niệu.
Tài liệu tham khảo
[1] Quy NN, Dao DA, Chau BNM, Study the
relationship between serum 25-Hydroxyvitamin
D levels with kidney damage in diabetic
patients, Journal of Medicine and Pharmacy-Hue
University of Medicine and Pharmacy, 01/2021,
99–104.
[2] Son NT, Khue LN, Dang TH et al., Guidelines
for Diagnosis and treatment of type 2 diabetes,
Ministry of Health, 2020.
[3] Boer IH de, Chan JCN, KDIGO 2020 Clinical
Practice Guideline for Diabetes Management in
Chronic Kidney Disease, Kidney International,
2020, 98(4):S1-S115.
[4] Cao Z, Cooper ME, Pathogenesis of diabeticnephropathy. J Diabetes Investig. 2011;2(4):243-
247. doi:10.1111/j.2040-1124.2011.00131.
[5] Hong S, Kim YB, Choi HS et al., Association of
Vitamin D Deficiency with Diabetic Nephropathy.
Endocrinol Metab (Seoul), 2021, 36(1), 106–113.
[6] International Diabetes Federation, IDF Diabetes
Atlas: Global Fact sheet, 2019.
[7] Kondo M, Toyoda M, Miyatake H et al., The
Prevalence of 25-hydroxyvitamin D Deficiency
in Japanese Patients with Diabetic Nephropathy.
Intern Med, 2016, 55(18), 2555–2562.
[8] Michael FH, Neil CB, Heike ABF et al.,
Evaluation, Treatment, and Prevention of Vitamin
D Deficiency: an Endocrine Society Clinical
Practice Guideline. Clinical Practice Guideline.
2011; 96(7):1911-1930.
[9] Wang Y, Deb DK, Zhang Z et al., Vitamin D
Receptor Signaling in Podocytes Protects against
Diabetic Nephropathy. J Am Soc Nephrol, 2012,
23(12), 1977–1986.
[10] Xie S, Huang L, Cao W et al., Association between
serum 25-hydroxyvitamin D and diabetic kidney
disease in Chinese patients with type 2 diabetes.
PLoS One, 2019, 14(4).
[11] Zeeuw D, Agarwal R, Amdahl M et al., Selective
vitamin D receptor activation with paricalcitol for
reduction of albuminuria in patients with type 2
diabetes (VITAL study): a randomised controlled
trial. Lancet, 2010, 376(9752), 1543–1551.
relationship between serum 25-Hydroxyvitamin
D levels with kidney damage in diabetic
patients, Journal of Medicine and Pharmacy-Hue
University of Medicine and Pharmacy, 01/2021,
99–104.
[2] Son NT, Khue LN, Dang TH et al., Guidelines
for Diagnosis and treatment of type 2 diabetes,
Ministry of Health, 2020.
[3] Boer IH de, Chan JCN, KDIGO 2020 Clinical
Practice Guideline for Diabetes Management in
Chronic Kidney Disease, Kidney International,
2020, 98(4):S1-S115.
[4] Cao Z, Cooper ME, Pathogenesis of diabeticnephropathy. J Diabetes Investig. 2011;2(4):243-
247. doi:10.1111/j.2040-1124.2011.00131.
[5] Hong S, Kim YB, Choi HS et al., Association of
Vitamin D Deficiency with Diabetic Nephropathy.
Endocrinol Metab (Seoul), 2021, 36(1), 106–113.
[6] International Diabetes Federation, IDF Diabetes
Atlas: Global Fact sheet, 2019.
[7] Kondo M, Toyoda M, Miyatake H et al., The
Prevalence of 25-hydroxyvitamin D Deficiency
in Japanese Patients with Diabetic Nephropathy.
Intern Med, 2016, 55(18), 2555–2562.
[8] Michael FH, Neil CB, Heike ABF et al.,
Evaluation, Treatment, and Prevention of Vitamin
D Deficiency: an Endocrine Society Clinical
Practice Guideline. Clinical Practice Guideline.
2011; 96(7):1911-1930.
[9] Wang Y, Deb DK, Zhang Z et al., Vitamin D
Receptor Signaling in Podocytes Protects against
Diabetic Nephropathy. J Am Soc Nephrol, 2012,
23(12), 1977–1986.
[10] Xie S, Huang L, Cao W et al., Association between
serum 25-hydroxyvitamin D and diabetic kidney
disease in Chinese patients with type 2 diabetes.
PLoS One, 2019, 14(4).
[11] Zeeuw D, Agarwal R, Amdahl M et al., Selective
vitamin D receptor activation with paricalcitol for
reduction of albuminuria in patients with type 2
diabetes (VITAL study): a randomised controlled
trial. Lancet, 2010, 376(9752), 1543–1551.